Search

Your search keyword '"Bhaskar N"' showing total 34 results
Start Over Author "Bhaskar N" Journal cancer (0008543x)
34 results on '"Bhaskar N"'

1. Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience.

Author

Leary, Sarah E. S., Wozniak, Amy W., Billups, Catherine A., Wu, Jianrong, McPherson, Valerie, Neel, Michael D., Rao, Bhaskar N., and Daw, Najat C.

Subjects
CANCER chemotherapy, OSTEOSARCOMA in children, OSTEOSARCOMA, METASTASIS, LUNG cancer diagnosis, CANCER relapse, PATIENTS, DIAGNOSIS
Abstract

BACKGROUND Chemotherapy has improved the outcome of patients with newly diagnosed osteosarcoma, but its role in relapsed disease is unclear. METHODS We reviewed the records of all patients who were treated for relapsed high-grade osteosarcoma at our institution between 1970 and 2004. Postrelapse event-free survival (PREFS) and postrelapse survival (PRS) were estimated, and outcome comparisons were made using an exact log-rank test. RESULTS The 10-year PREFS and PRS of the 110 patients were 11.8% ± 3.5% and 17.0% ± 4.3%, respectively. Metastasis at initial diagnosis (14%), and relapse in lung only (75%) were not significantly associated with PREFS or PRS. Time from initial diagnosis to first relapse (RL1) ≥18 months (43%), surgery at RL1 (76%), and ability to achieve second complete remission (CR2, 56%) were favorably associated with PREFS and PRS ( P ≤ 0.0002). In patients without CR2, chemotherapy at RL1 was favorably associated with PREFS ( P = 0.01) but not with PRS. In patients with lung relapse only, unilateral relapse and number of nodules ( ≤ 3) were associated with better PREFS and PRS ( P ≤ 0.0005); no patients with bilateral relapse survived 10 years. The median PREFS after treatment with cisplatin, doxorubicin, methotrexate, and ifosfamide was 3.5 months (95% confidence interval, 2.1-5.2), and the median PRS was 8.2 months (95% confidence interval, 5.2-15.1). CONCLUSIONS Late relapse, surgical resection, and unilateral involvement (in lung relapse only) favorably impact outcome after relapse. Surgery is essential for survival; chemotherapy may slow disease progression in patients without CR2. These data are useful for designing clinical trials that evaluate novel agents. Cancer 2013;119:2645-2653. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

2. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.

Author

Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, Santana VM, Daw, Najat C, Neel, Michael D, Rao, Bhaskar N, Billups, Catherine A, Wu, Jianrong, Jenkins, Jesse J, Quintana, Juan, Luchtman-Jones, Lori, Villarroel, Milena, and Santana, Victor M

Abstract

Background: The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue. In the previous OS91 trial, the treatment of localized disease with carboplatin, ifosfamide, doxorubicin, and HDMTX yielded outcomes comparable to those of cisplatin-based regimens and caused less toxicity. To build on this experience, the authors conducted a multi-institutional trial (OS99) that evaluated the efficacy of carboplatin, ifosfamide, and doxorubicin without HDMTX in patients with newly diagnosed, localized, resectable osteosarcoma.Methods: Treatment was comprised of 12 cycles of chemotherapy administered over 35 weeks: 3 cycles of carboplatin (dose targeted to area under the concentration-time curve of 8 mg/mL × min on Day 1) and ifosfamide (at a dose of 2.65 g/m(2) daily ×3 days) and 1 cycle of doxorubicin (at a dose of 25 mg/m(2) daily ×3 days) before surgical resection, followed by 2 additional cycles of the combination of carboplatin and ifosfamide and 3 cycles each of doxorubicin (25 mg/m(2) daily ×2 days) combined with ifosfamide or carboplatin.Results: A total of 72 eligible patients (median age, 13.4 years) were enrolled between May 1999 and May 2006. Forty of the 66 (60.6%) evaluable patients had good histologic responses (>90% tumor necrosis) to preoperative chemotherapy. The estimated 5-year event-free survival rate was 66.7% ± 7.0% for the OS99 trial compared with 66.0% ± 6.8% for the OS91 trial (P = .98). The estimated 5-year survival rate was 78.9% ± 6.3% for the OS99 trial and 74.5% ± 6.3% for the OS91 trial (P = .40).Conclusions: The regimen used in the OS99 trial was found to produce outcomes comparable to those of cisplatin-containing or HDMTX-containing regimens. This therapy offers a good alternative for patients, particularly those who demonstrate an intolerance of HDMTX, and for institutions that cannot provide pharmacokinetic monitoring for MTX. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

3. Analysis of prognostic factors in ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital studies.

Author

Carlos Rodríguez‐Galindo, Tiebin Liu, Matthew J. Krasin, Jianrong Wu, Catherine A. Billups, Najat C. Daw, Sheri L. Spunt, Bhaskar N. Rao, Victor M. Santana, and Fariba Navid

Subjects
TUMORS, CANCER invasiveness, ONCOLOGY, HEALTH outcome assessment, LEUKEMIA
Abstract

Advances in systemic and local therapies have improved outcomes for patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed, a critical review of data from past treatment eras is needed to identify clinically relevant risk groups.The authors reviewed the records of 220 patients with ESFT who were treated on protocols at St. Jude Children's Research Hospital from 1979 to 2004. Two treatment eras were defined. Factors predictive of outcome were analyzed to identify distinct risk groups.The median age at diagnosis was 13.7 years (range, 1.1–25.2 years). Metastatic disease was associated with tumors measuring >8 cm (P = .002) and axial location (P = .014). The 5‐year overall survival (OS) estimate (63.5% ± 3.5%) did not appear to differ by protocol. Tumor stage and size were found to be the only independent predictors of outcome. Treatment era and type of local control therapy were found to influence the outcome of patients with localized disease. Four risk groups were defined: favorable risk (age <14 years with localized, nonpelvic tumors), intermediate risk (localized, age ≥14 years, or pelvic tumors), unfavorable‐pulmonary (isolated lung metastases), and unfavorable‐extrapulmonary (extrapulmonary metastases). The 5‐year OS estimates for these groups were 88.1% ± 4.4%, 64.9% ± 5.2%, 53.8% ± 9.4%, and 27.2% ± 7.3%, respectively (P < .001). The incidence of therapy‐related leukemia was significantly higher during the second treatment era, when more intensified regimens were used (6.1% ± 2.7% vs 0% ± 0%; P = .005).Risk stratification schemes such as this should be used to prospectively evaluate novel risk‐based therapies. Studies of biologic pathways may help to refine this model. Cancer 2007. © 2007 American Cancer Society. [ABSTRACT FROM AUTHOR]

Published
2007

4. Telangiectatic Osteosarcoma: The St. Jude Children's Research Hospital's Experience.

Author

Weiss, Aaron, Khoury, Joseph D., Hoffer, Fredric A., Jianrong Wu, Billups, Catherine A., Heck, Robert K., Quintana, Juan, Poe, Debbie, Rao, Bhaskar N., and Daw, Najat C.

Subjects
CANCER research, CANCER histopathology, TELANGIECTASIA, OSTEOSARCOMA, CANCER risk factors
Abstract

The article discusses a research which aimed to characterize the histologic, radiologic and clinical features of telangiectatic osteosarcoma (TOS). The records, pathology material, and imaging studies from all patients who were treated between 1978 and 2005 at St. Jude Children's Research Hospital were reviewed. The study analyzed risk factors that may be predictive of patient outcome, and compared the outcome of patients with TOS to that of patients with other high-grade osteosarcoma (OS) subtypes who were treated during the same period.

Published
2007
Full Text
View/download PDF

19. Hemangiopericytoma in children and infants.

Author

Rodriguez-Galindo, Carlos, Ramsey, Kirk, Jenkins, Jesse J., Poquette, Catherine A., Kaste, Sue C., Merchant, Thomas E., Rao, Bhaskar N., Pratt, Charles B., Pappo, Alberto S., Rodriguez-Galindo, C, Ramsey, K, Jenkins, J J, Poquette, C A, Kaste, S C, Merchant, T E, Rao, B N, Pratt, C B, and Pappo, A S

Published
2000
Full Text
View/download PDF

33. Post-irradiation malignant mesothelioma.

Author

Pappo, Alberto S., Santana, Victor M., Furman, Wayne L., Kun, Larry E., Walter, Andrew W., Jenkins, Jesse J., Rao, Bhaskar N., Pratt, Charles B., Pappo, A S, Santana, V M, Furman, W L, Kun, L E, Walter, A W, Jenkins, J J, Rao, B N, and Pratt, C B

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results